Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

Deregulation of the cyclin D‐CDK4/6‐INK4‐RB pathway leading to uncontrolled cell proliferation, is frequently observed in breast cancer. Currently, three selective CDK4/6 inhibitors have been FDA approved: palbociclib, ribociclib and abemaciclib. Despite promising clinical outcomes, intrinsic or acq...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Kamal, An, Hee‐Jung, Kim, Seung Ki, Lee, Seung Ah, Kim, Sewha, Lim, Sun Min, Kim, Gun Min, Sohn, Joohyuk, Moon, Yong Wha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767051/
https://www.ncbi.nlm.nih.gov/pubmed/30478914
http://dx.doi.org/10.1002/ijc.32020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6767051/
https://www.ncbi.nlm.nih.gov/pubmed/30478914
http://dx.doi.org/10.1002/ijc.32020

Ejemplares similares